ENO2 and non-small cell lung carcinoma: For instance, in our model, an advanced NSCLC patient has an N stage of N3 (40.7 points), an NLR exceeding 2.565 (43.5 points), a D-dimer level below 300.0 ng/ml (0 points), an NSE level surpassing 5.605 μg/L (37 points), an SCC level above 0.445 ng/ml (40 points), the presence of driver alterations (0 points), and is receiving targeted therapy as the first-line treatment (52.8 points).